Your browser doesn't support javascript.
loading
Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis.
Okada, Masamitsu; Yamashita, Satoshi; Ueyama, Hidetsugu; Ishizaki, Masatoshi; Maeda, Yasushi; Ando, Yukio.
Afiliación
  • Okada M; Department of Neurology, National Hospital Organization, Kumamoto Saishunso National Hospital, Koshi, Japan.
  • Yamashita S; Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
  • Ueyama H; Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
  • Ishizaki M; Department of Neurology, National Hospital Organization, Kumamoto Saishunso National Hospital, Koshi, Japan.
  • Maeda Y; Department of Neurology, National Hospital Organization, Kumamoto Saishunso National Hospital, Koshi, Japan.
  • Ando Y; Department of Neurology, National Hospital Organization, Kumamoto Saishunso National Hospital, Koshi, Japan.
eNeurologicalSci ; 11: 11-14, 2018 Jun.
Article en En | MEDLINE | ID: mdl-29928711
BACKGROUND AND PURPOSE: Oxidative stress has been implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS). Edaravone, a free radical scavenger, was approved as a therapeutic drug for ALS in 2015 in Japan. A phase 3 clinical trial demonstrated a smaller decline in ALS functional scale scores compared with placebo. However, the long-term effects of edaravone on ALS patients remain unclear. This study aimed to retrospectively investigate the long-term effects of edaravone on the survival of ALS patients. METHODS: We retrospectively analyzed 27 consecutive patients with ALS who were treated with edaravone and 30 consecutive ALS patients who were not treated with edaravone between 2010 and 2016. RESULTS: The differences of ALSFRS-R scores from baseline to 6 months was significantly reduced in the edaravone group, compared to the control group. The changes in serum creatinine, as a possible marker of ALS severity, from baseline to 6 and 12 months were significantly improved in the edaravone group, compared to the control group. The survival rate was significantly improved in the edaravone group compared with control patients. CONCLUSION: Our retrospective single-center analysis suggests slower progression and better prognosis of ALS patients with edaravone treatment. Further investigation, including prospective multicenter analysis, is warranted to confirm the usefulness of edaravone for a better prognosis of ALS.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: ENeurologicalSci Año: 2018 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: ENeurologicalSci Año: 2018 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Países Bajos